3rd Annual Getzlaf Golf Shootout to Feature Anaheim Ducks Captain Ryan Getzlaf and Fellow Teammates Playing in Charity Tournament to Benefit CureDuchenne

Newport Beach, Calif.

 

Newport Beach, Calif., September 5, 2013: Ryan Getzlaf, captain of the Anaheim Ducks, is hosting the third annual Getzlaf Golf Shootout on September 7 and 8 to benefit CureDuchenne, a nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy. CureDuchenne is pleased to announce that Patriot Environmental Services, the premier provider of comprehensive environmental services in the southwestern United States, is the title sponsor of the Getzlaf Golf Shootout. Patriot is sponsoring the event in memory of Justin Paul Monastesse who lived with Duchenne for more than 25 years and passed on August 1, 2001.

The Getzlaf Golf Shootout charity golf event will be held at the Monarch Beach Golf Links on Sunday, September 8 in Dana Point. Each foursome will be teamed up with a professional hockey player as a fifth player. Confirmed current and former Anaheim Ducks players include:

  • Ryan Getzlaf
  • Brian Allen
  •  Matt Beleskey
  •  Francois Beauchemin
  • Andrew Cogliano
  • Viktor Fasth
  • Cam Fowler
  • Peter Holland
  • Kent Huskins
  • Craig Johnson
  • Sauk Koivu
  • Brad Lauer
  • Todd Marchant
  • Kyle Palmieri
  • Corey Perry
  • Dustin Penner
  •  Sean Pronger
  • Luca Sbisa
  • Teemu Selanne
  • Brad Staubitz
  • Daniel Winnik
  • Nolan Yonkmen

A pre-golf dinner reception will be held at Sutra in Costa Mesa on Saturday, September 7. Hockey fans are welcome to meet and mingle with players and celebrities at the reception that will include dinner, drinks, a program and a live and silent auction. Auction items include experiences, travel and autographed memorabilia. Golf foursomes cost $2,800. Individual tickets to the reception are $100. For more information and to register, click here. 

 

Duchenne is a progressive muscle-wasting disease that impacts one in 3,500 boys. Boys are usually diagnosed at age 5, are in a wheelchair by 12 and most don’t live past their mid-20s. CureDuchenne supports the translation of research and development programs into the clinic to focus on developing potential therapies to transform the treatment of Duchenne. CureDuchenne has funded seven research projects that have gone into human clinical trials.

 

“We look forward to supporting CureDuchenne this weekend at the annual Getzlaf Golf Shootout,” said Getzlaf.  “Duchenne is a devastating disease that impacts boys and robs them of the ability to walk, run and play sports. CureDuchenne continues to fund critical research to bring treatment to all boys with Duchenne.”

 

“Ryan and Paige Getzlaf are gracious and generous supporters of CureDuchenne,” said Debra Miller, founder of CureDuchenne. “We are in a race against time to help our son and other young men and boys who live with Duchenne. It is urgent to cure Duchene now to help this generation of Duchenne boys.”

Sponsors include Patriot Environmental Services, The Sports Corporation, Bauer Hockey, The California Endowment, CNC Motors, The Hundred Acre Wine Group and Straub Distributing.

For more information on CureDuchenne go to www.cureduchenne.org or call 949-872-2552.

 

Follow us on Facebook, Twitter and YouTube.

 

About CureDuchenne
CureDuchenne is a national nonprofit organization located in Newport Beach, Calif., dedicated to finding a cure for Duchenne, the most common and most lethal form of muscular dystrophy. As the leading genetic killer of young boys, Duchenne affects more than 300,000 boys worldwide.

 

CureDuchenne has garnered international attention for its efforts to raise funds and awareness for Duchenne. With the help of CureDuchenne’s distinguished international panel of Scientific Advisors, funds raised by CureDuchenne support the most promising research aimed at treating and curing Duchenne. To date, seven CureDuchenne research projects have made their way into human clinical trials – a unique accomplishment as few health-related nonprofits have been successful in being a catalyst for human clinical trials.

###